Speaker Profile
Ph.D., Associate Professor of Biomedical Data Science, Stanford U.
Biography
James an Associate Professor of Biomedical Data Science and, by courtesy, of Computer Science and Electrical Engineering at Stanford University. James works on making AImore reliable, human-compatible and statistically rigorous, and am especially interested in applications in human disease and health. James received his Ph.D from Harvard in 2014, and was at one time a member of Microsoft Research, a Gates Scholar at Cambridge and a Simons fellow at U.C. Berkeley. James joined Stanford in 2016 and am excited to also be a Chan-Zuckerberg Investigator. We are also a part of the Stanford AI Lab. His research is supported by two Chan-Zuckerberg Biohub Investigator Awards, the Sloan Fellowship, the NSF CAREER Award, a Top Ten Clinical Achievement Award and faculty awards from Google, Adobe and Amazon.
Talk
AI Scientist Agents for Drug Discoveries
Ill introduce the Virtual Laba collaborative team of AI scientist agents conducting in silico research meetings to tackle open-ended RD projects. The Virtual Lab designed new nanobody binders to recent Covid variants that we experimentally validated.
AI for Emerging Therapeutics Showcase:
Stanford University
Stanford
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
